Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

26.88 -0.72 (-2.61%)
Streaming Delayed Price Updated: 3:47 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
A Closer Look at 5 Analyst Recommendations For Exelixis
Via Benzinga
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
From Exelixis, Inc.
Via Business Wire
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
From Exelixis, Inc.
Via Business Wire
NASDAQ:EXEL, an undervalued stock with good fundamentals.
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Expert Outlook: Exelixis Through The Eyes Of 5 Analysts
Via Benzinga
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed significant PFS benefit but OS did not achieve statistical significance.... 
Via Benzinga
Exposures Product Safety
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by... 
Via Benzinga
Topics Stocks
Exposures US Equities
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024
EXEL stock results show that Exelixis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainability of uptrend. 
Via Benzinga
Topics Stocks
Exposures US Equities
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
From Exelixis, Inc.
Via Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
Via Chartmill
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at EXELIXIS INC (NASDAQ:EXEL), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
EXELIXIS INC (NASDAQ:EXEL) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
From Exelixis, Inc.
Via Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
Via Chartmill
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
These stocks are both experts in their respective fields. 
Via The Motley Fool
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets. 
Via Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.